Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG PEN versus SEMGLEE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG PEN versus SEMGLEE.
HUMALOG PEN vs SEMGLEE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that binds to the insulin receptor, activating tyrosine kinase activity and downstream signaling pathways (e.g., PI3K/Akt) to promote glucose uptake in skeletal muscle and adipose tissue, inhibit hepatic gluconeogenesis, and regulate lipid and protein metabolism.
Long-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake (especially in skeletal muscle and fat) and inhibiting hepatic glucose production via binding to insulin receptors, activating the insulin receptor tyrosine kinase cascade.
Subcutaneously 0.5–1 unit/kg/day divided into multiple doses (usually 3 or more), administered 15 minutes before or immediately after meals.
Subcutaneous injection, 0.2 units/kg/day initially, adjusted based on blood glucose levels. Typical maintenance dose: 0.5-1 unit/kg/day.
None Documented
None Documented
Approximately 0.5-1 hour (rapid; subcutaneous absorption rate-limited).
18.3 hours; reflects protracted absorption from subcutaneous depot, enabling once-daily dosing
Renal: 60-80% of dose excreted as metabolites; remainder hepatobiliary and fecal.
Renal (30-80% as intact insulin); fecal (negligible)
Category C
Category C
Insulin Analog
Insulin Analog